- Home
- SPRY vs ATUS Comparison
SPRY vs ATUS Comparison
Compare SPRY & ATUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- ATUS
- Stock Information
- Founded
- SPRY 2015
- ATUS 2015
- Country
- SPRY United States
- ATUS United States
- Employees
- SPRY N/A
- ATUS N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- ATUS Cable & Other Pay Television Services
- Sector
- SPRY Health Care
- ATUS Telecommunications
- Exchange
- SPRY Nasdaq
- ATUS Nasdaq
- Market Cap
- SPRY 1.4B
- ATUS 1.2B
- IPO Year
- SPRY N/A
- ATUS 2017
- Fundamental
- Price
- SPRY $11.41
- ATUS $2.65
- Analyst Decision
- SPRY Strong Buy
- ATUS Hold
- Analyst Count
- SPRY 4
- ATUS 10
- Target Price
- SPRY $24.00
- ATUS $2.39
- AVG Volume (30 Days)
- SPRY 959.4K
- ATUS 3.2M
- Earning Date
- SPRY 11-13-2024
- ATUS 11-04-2024
- Dividend Yield
- SPRY N/A
- ATUS N/A
- EPS Growth
- SPRY N/A
- ATUS N/A
- EPS
- SPRY N/A
- ATUS N/A
- Revenue
- SPRY $2,568,000.00
- ATUS $9,021,002,000.00
- Revenue This Year
- SPRY $95,526.66
- ATUS N/A
- Revenue Next Year
- SPRY $275.98
- ATUS N/A
- P/E Ratio
- SPRY N/A
- ATUS N/A
- Revenue Growth
- SPRY 8460.00
- ATUS N/A
- 52 Week Low
- SPRY $5.02
- ATUS $1.52
- 52 Week High
- SPRY $18.51
- ATUS $3.66
- Technical
- Relative Strength Index (RSI)
- SPRY 32.88
- ATUS 53.25
- Support Level
- SPRY $11.76
- ATUS $2.45
- Resistance Level
- SPRY $14.50
- ATUS $2.72
- Average True Range (ATR)
- SPRY 0.75
- ATUS 0.16
- MACD
- SPRY -0.20
- ATUS 0.01
- Stochastic Oscillator
- SPRY 1.63
- ATUS 72.07
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About ATUS Altice USA Inc.
Altice Europe acquired privately held us cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4 million U.S. homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and business in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York and i24News, a news operation focused on the Middle East.